Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1992;29(5):409-11.
doi: 10.1007/BF00686013.

Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC Lung Cancer Cooperative Group

Affiliations
Clinical Trial

Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC Lung Cancer Cooperative Group

A S Planting et al. Cancer Chemother Pharmacol. 1992.

Abstract

A total of 24 patients presenting with small-cell lung cancer either resistant to or relapsing within 3 months after first-line treatment were entered in a phase II study of 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-(2-chloroethyl)-3- nitrosourea hydrochloride (ACNU). ACNU was given i.v. at a dose of 75 mg/m2 every 6 weeks. We observed a partial response of 7 months' duration in one patient and one case of stable disease that lasted for 6 months; all other subjects exhibited progressive disease. Two patients developed brain metastases during treatment. The toxicity of ACNU consisted mainly of bone marrow suppression, especially thrombocytopenia. At this dose and on this schedule, ACNU shows minimal activity as second-line treatment in small-cell lung cancer.

PubMed Disclaimer

References

    1. Gan. 1978 Aug;69(4):545-8 - PubMed
    1. Cancer Chemother Pharmacol. 1991;28(2):145-6 - PubMed
    1. Cancer Chemother Pharmacol. 1980;4(3):165-71 - PubMed
    1. Eur J Cancer Clin Oncol. 1987 Sep;23(9):1409-11 - PubMed
    1. Invest New Drugs. 1986;4(2):175-9 - PubMed

Publication types

LinkOut - more resources